Riskpilot← Back to searchSign inGet full accessMIFAMED ApS
APSDissolvedCVR 71169413Vassingerødvej 9Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19821 employees
Revenue 2020
—
EBITDA margin
—
+7% vs 2019
Equity ratio
99.0%
Financial strength
Net profit 2020
DKK -21K
-4% vs 2019
| Revenue | — | — |
| EBITDA | DKK -12K | +7% |
| Net profit | DKK -21K | -4% |
| Total assets | DKK 2,3M | +0% |
| Equity | DKK 2,3M | -1% |
| Employees | — | — |
Legal name
MIFAMED ApS
CVR number
71169413
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2. juli 1982
Share capital
DKK 200.000
Employees
1
VAT registered
No
Audit selected
No
Last report
2020-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening, eller af to direktører i forening, eller af den samlede bestyrelse
Address
Vassingerødvej 9
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -26 | 79 | -31 | — | — | — | — | — | — |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -26 | 79 | -31 | -12 | -12 | -6 | -0 | -13 | -12 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -26 | 79 | -31 | -12 | -12 | -6 | -0 | -13 | -12 |
| Net financials | 198 | -277 | 56 | -7 | -12 | 4 | -4 | -13 | -15 |
| Profit before tax | 172 | -198 | 25 | -19 | -24 | -1 | -4 | -26 | -27 |
| Tax | 43 | -50 | 6 | -5 | -5 | -0 | -1 | -6 | -6 |
| Net profit | 129 | -149 | 19 | -15 | -19 | -1 | -3 | -20 | -21 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2.699 | 2.910 | 2.403 | 2.383 | 2.374 | 2.365 | 2.362 | 2.345 | 2.333 |
| Equity | 2.519 | 2.370 | 2.389 | 2.375 | 2.356 | 2.355 | 2.352 | 2.331 | 2.310 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 180 | 540 | 14 | 8 | 18 | 10 | 10 | 13 | 23 |
| Total debt | 180 | 540 | 14 | 8 | 18 | 10 | 10 | 13 | 23 |
EBITDA margin
-1182700.0%
This company
15.8%
Market median
-7485543% vs market
20122020
Equity ratio
99.0%
This company
38.2%
Market median
+159% vs market
20122020
Return on equity
-0.9%
This company
18.4%
Market median
-105% vs market
20122020
Net profit margin
-2125500.0%
This company
8.1%
Market median
-26240841% vs market
20122020
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122020
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20122020
- Annual report 2020Filed via CVR / Virk · Period 2019-04-01 – 2020-03-31
- Annual report 2019Filed via CVR / Virk · Period 2018-04-01 – 2019-03-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-03-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-05-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CM Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
PL Management | Management | 2012 | — | — |
JK Management | Management | 1982 | — | — |
MM Management | Management | 2003 | — | — |
NH Audit | Audit | 1982 | — | — |
CI Management | Management | 2008 | — | — |
PG Management | Management | 1982 | — | — |
JE Management | Management | 1998 | — | — |
PG Management | Management | 1982 | — | — |
MM Chief Executive Officer | Chief Executive Officer | 2012 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2012 | — | — | |
| Board of Directors | 2012 | — | — | |
| Deputy Chairman | 2012 | — | — | |
| Deputy Chairman | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
MISSIONPHARMA GROUP ApS | Company | 100.0% | 100.0% | 2009 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MIFAMED ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Christian Monrad Overgaard | Chief Executive Officer | 0 companies |
| Poul Lindof | Management | 0 companies |
| Jannik Kenneth Rosenkrans Jensen | Management | 0 companies |
| Martin Møller Olesen | Management | 0 companies |
| Niels Harder | Audit | 0 companies |
| Christian Ilsøe | Management | 0 companies |
| Poul Ginnerup | Management | 0 companies |
| Jørgen Edvard Laursen | Management | 0 companies |
| Paule Georgette Ginnerup | Management | 0 companies |
| Mikkel Mørkedal Wakefield | Chief Executive Officer | 0 companies |
| Annie Renée Simonne Dateu | Board of Directors | 0 companies |
| Aymeric Erouart | Board of Directors | 0 companies |
| Jean-Marc Pierre Rene Leccia | Chairman | 0 companies |
| Eric Pierre Jean Muris | Board of Directors | 0 companies |
| Denis Georges Fernand Maurice | Deputy Chairman | 0 companies |
| Kim Erik Ginnerup | Deputy Chairman | 0 companies |